which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.\nFructus polygoni orientalis (FPO) is widely used in clinical practice in China, especially in treatment of liver diseases including\nviral hepatitis, liver fibrosis, and liver cirrhosis. However, its pharmacokinetic (PK) alterations in liver fibrotic rats have rarely been\nreported. To study whether taxifolin, one of the main flavonoids in FPO can be absorbed into blood after oral administration of\nFPO extract and to compare the differences in pharmacokinetic parameters of taxifolin to normal and liver fibrotic rats induced by\nporcine serum (PS), a UPLC-MS/MS method was developed and validated for determination of taxifolin in rat plasma using\npuerarin as the internal standard (IS). All validation parameters met the acceptance criteria according to regulatory guidelines.\nThe results indicated that after treatment of rats with PS alone for 12 weeks, the liver fibrotic model group was built successfully..................
Loading....